Nkarta to Participate at Upcoming Investor Conferences
November 02, 2022 08:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 11, 2022 16:02 ET
|
Nkarta, Inc.
Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company’s platform for...
Nkarta Announces Key Senior Leadership Team Appointments
July 25, 2022 16:31 ET
|
Nkarta, Inc.
Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to support rapid development of allogeneic,...
Nkarta to Participate at Upcoming Investor Conference
May 31, 2022 07:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today...
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
May 16, 2022 16:02 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
May 12, 2022 16:02 ET
|
Nkarta, Inc.
Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of 1B or 1.5B CAR NK cells per dose achieved...
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
April 28, 2022 16:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
April 25, 2022 23:19 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
Nkarta Announces Proposed Public Offering of Common Stock
April 25, 2022 16:01 ET
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today...
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 25, 2022 07:00 ET
|
Nkarta, Inc.
NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60%...